Innate Pharma is forecast to grow earnings and revenue by 49.8% and 46% per annum respectively while EPS is expected to grow by 111% per annum.
Key information
49.8%
Earnings growth rate
111.02%
EPS growth rate
Biotechs earnings growth
23.8%
Revenue growth rate
46.0%
Future return on equity
n/a
Analyst coverage
Good
Last updated
14 May 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
XTRA:IDD - Analysts future estimates and past financials data (EUR Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
41
-51
-62
-54
3
12/31/2027
65
-18
27
35
6
12/31/2026
31
-29
-19
-11
6
12/31/2025
9
-49
-53
-53
N/A
9/30/2025
11
-48
-47
-47
N/A
6/30/2025
13
-46
-41
-41
N/A
3/31/2025
16
-48
-24
-24
N/A
12/31/2024
20
-49
-7
-7
N/A
9/30/2024
27
-42
-14
-12
N/A
6/30/2024
34
-34
-20
-18
N/A
3/31/2024
48
-21
-28
-25
N/A
12/31/2023
62
-8
-35
-33
N/A
9/30/2023
57
-35
-34
-32
N/A
6/30/2023
52
-63
-33
-32
N/A
3/31/2023
55
-60
-27
-25
N/A
12/31/2022
58
-58
-20
-19
N/A
9/30/2022
57
-40
-24
-23
N/A
6/30/2022
57
-22
-28
-26
N/A
3/31/2022
41
-34
-44
-42
N/A
12/31/2021
25
-45
-60
-58
N/A
6/30/2021
46
-8
-27
-25
N/A
3/31/2021
58
-4
-45
-38
N/A
12/31/2020
70
-1
-63
-52
N/A
9/30/2020
67
-54
-78
-67
N/A
6/30/2020
63
-44
-93
-83
N/A
3/31/2020
75
-33
-62
-24
N/A
12/31/2019
85
8
-30
35
N/A
9/30/2019
108
5
N/A
48
N/A
6/30/2019
130
31
N/A
61
N/A
3/31/2019
112
17
N/A
14
N/A
12/31/2018
94
3
N/A
-33
N/A
9/30/2018
70
-19
N/A
-46
N/A
6/30/2018
46
-40
N/A
-59
N/A
3/31/2018
45
-44
N/A
-53
N/A
12/31/2017
44
-48
N/A
-48
N/A
9/30/2017
55
-28
N/A
-43
N/A
6/30/2017
66
-8
N/A
-38
N/A
3/31/2017
66
3
N/A
-37
N/A
12/31/2016
66
13
N/A
-37
N/A
9/30/2016
53
5
N/A
-33
N/A
6/30/2016
41
-2
N/A
-29
N/A
3/31/2016
33
-4
N/A
86
N/A
12/31/2015
25
-7
N/A
202
N/A
9/30/2015
17
-13
N/A
200
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IDD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IDD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IDD's revenue (46% per year) is forecast to grow faster than the German market (6.6% per year).
High Growth Revenue: IDD's revenue (46% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IDD's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/18 01:34
End of Day Share Price
2026/07/17 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innate Pharma S.A. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.